Zepzelca Trial Fails
Jazz Pharmaceuticals' Zepzelca LAGOON Trial Misses Primary Overall Survival Goal for Lung Cancer
Key Points
The Phase 3 LAGOON study was a randomized, open-label trial enrolling 724 patients from more than 200 sites globally; it studied extensive-stage SCLC patients who had progressed after first-line platinum-based chemotherapy.
On a hazard-ratio basis versus control, Jazz reported a hazard ratio of 1.190 for Zepzelca monotherapy and 0.902 for Zepzelca plus irinotecan.
Treatment-related adverse events were common across arms: 78.5% with Zepzelca monotherapy, 95% with Zepzelca plus irinotecan, and 93.8% with the control regimen.
Jazz said LAGOON enrolled a broader patient population than the Phase 2 program that supported Zepzelca’s second-line accelerated approval, including patients with CNS involvement; the company added that efficacy in patients without CNS involvement was “more comparable to the control arm.”
In the wake of the LAGOON readout, Jazz told investors that the study results “will not impact the company’s 2026 guidance.”
Jazz Pharmaceuticals' Phase 3 LAGOON trial of Zepzelca (lurbinectedin) failed to beat standard chemotherapy in relapsed small cell lung cancer, the company announced on June 12, 2026. Neither Zepzelca alone nor Zepzelca combined with irinotecan produced a statistically significant survival improvement over the control arm, according to Morningstar.
The failure is a blow to the drug's second-line indication — the very label it first won in 2020. Jazz's stock slipped in premarket trading, though the company said the results "will not impact the company's 2026 guidance," pointing to a separate first-line approval secured in 2025 as its commercial lifeline, MarketScreener reported.
LAGOON's Numbers Show Zepzelca Failed to Beat Control
LAGOON enrolled 724 patients across more than 200 sites worldwide. All had extensive-stage SCLC that progressed after first-line platinum-based chemotherapy. The trial had three arms: Zepzelca alone, Zepzelca plus irinotecan, and investigators' choice of topotecan or irinotecan as the control.
Zepzelca monotherapy posted a median overall survival of 8.7 months — worse than the control arm's 10.7 months — yielding a hazard ratio of 1.190, meaning patients on Zepzelca alone actually fared worse. The combo arm reached 10.9 months versus the control's 10.7 months, a hazard ratio of 0.902, but that difference was not statistically significant, according to Morningstar. Jazz noted the control arm performed better than historical averages, where topotecan typically produces 6–8 months of survival, making it harder for Zepzelca to show a clear win.
A Broader Patient Pool Made an Already Hard Trial Harder
Jazz acknowledged that LAGOON enrolled a wider group of patients than the Phase 2 study that first got Zepzelca approved in 2020. Crucially, LAGOON included patients with central nervous system involvement — brain metastases — who were excluded from the earlier trial.
The company said efficacy in patients without CNS involvement was "more comparable to the control arm," suggesting the sicker, broader population dragged down results. Side effects were common across all arms: 78.5% of patients on Zepzelca monotherapy had treatment-related adverse events, versus 95% on the combo and 93.8% on control. Jazz said no new safety concerns emerged, per MarketScreener.
Jazz Pivoted to First-Line Use Before the Trial Failed
Jazz did not wait for LAGOON to read out before securing Zepzelca's future. The company ran a separate trial — IMforte — testing the drug as a maintenance therapy right after first-line chemotherapy, rather than after relapse. That trial succeeded. The FDA granted full approval for Zepzelca plus atezolizumab in the first-line maintenance setting on October 2, 2025, according to Morningstar.
Jazz CMO Rob Iannone stated the company believes Zepzelca's "most beneficial use is in the first-line maintenance setting." The European Commission also approved Zepzelca for that indication on June 1, 2026 — just 11 days before the LAGOON failure was announced. Jazz said the drug had been projected to reach $700 million in peak annual sales.
FDA Must Decide Whether to Pull the Second-Line Label
LAGOON was the designated confirmatory trial for Zepzelca's original 2020 accelerated approval in relapsed SCLC. Under the FDA's accelerated approval rules, a drug must verify its clinical benefit in a follow-up trial or risk losing that label. With LAGOON failing, the FDA now faces pressure to withdraw the second-line indication, per MarketScreener.
Jazz said it will discuss post-marketing next steps with the FDA directly. This is not Zepzelca's first Phase 3 failure — the ATLANTIS combo trial also missed its overall survival endpoint in December 2021. Critics have argued the drug has "failed its way to success" by shifting to earlier treatment lines rather than proving benefit in the setting it was first approved for. Jazz's first-line maintenance approval remains intact and is not affected by the LAGOON outcome, according to TradingView.
Sentiment
Mostly NegativePublishers
17
Articles
34
Reach
51
